UNIMED Medical Center EOOD

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)4 trials
• Psoriasis3 trials
• Vitiligo3 trials
• Hidradenitis suppurativa2 trials
• Asthma1 trial
• Atrial fibrillation1 trial

Phase

• Phase 38 trials
• Phase 24 trials
• Phase 41 trial

Status

• Active, not recruiting8 trials
• Completed2 trials
• Recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Incyte Corporation4 trials
• Takeda3 trials
• Chiesi Farmaceutici S.p.A.1 trial
• Corvus Pharmaceuticals, Inc.1 trial
• Janssen Research & Development, LLC1 trial
• and 3 more

Running trials

• Recruiting

  BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])

  NCT07666490· Phase 4· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

  NCT07441395· Phase 2· Corvus Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis

  2025-522113-35-00· Phase 2· Triveni Bio Inc.· Source

• Active, not recruiting

  A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

  NCT07277660· Phase 2· UCB Biopharma SRL· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

  NCT06804811· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

  NCT06958211· Phase 3· Incyte Corporation· Source

• Recruiting

  Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

  NCT06855498· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Takeda· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

  NCT06113471· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

  NCT06136741· Phase 2· Nektar Therapeutics· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Hidradenitis suppurativa1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Takeda· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· Phase 3· Takeda· Source